CriticalSelective irreversible monoamine oxidase B inhibitor×Other opioids
Updated · Methodology
Mechanism
Rasagiline is a potent, irreversible inhibitor of monoamine oxidase (MAO) type B (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.1). MAO breaks down catecholamines and serotonin in the nervous system and other tissues (rasagiline label, US Food and Drug Administration, FDA, section 12.1). At recommended doses rasagiline acts selectively on MAO-B, but this selectivity falls as the dose rises above the recommended range (FDA rasagiline label, sections 5.1 and 12.1). Tramadol is a centrally acting opioid analgesic. Inhibition of noradrenaline reuptake and increased serotonin release add to its analgesic effect (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Interactions of MAO inhibitors with opioids may present as serotonin syndrome or opioid toxicity (FDA tramadol label, section 7). According to the Spanish tramadol SmPC, MAO inhibitors taken within 14 days before pethidine have caused life-threatening effects on the central nervous system, breathing and circulation. The SmPC does not rule out the same reactions with tramadol (tramadol SmPC, AEMPS, section 4.5). A clinically significant interaction through liver enzymes is unlikely: at therapeutic concentrations rasagiline is not expected to affect substrates of cytochrome P450 (CYP) enzymes, including CYP2D6 and CYP3A4 (rasagiline SmPC, EMA, section 4.5), and these are exactly the enzymes that metabolise tramadol (tramadol SmPC, AEMPS, sections 4.4 and 4.5).
Symptoms
Serotonin syndrome has also been reported with rasagiline and tramadol: confusion, hypomania, hallucinations, agitation, delirium, headache, coma, fainting, shivering, sweating, high fever, high blood pressure, fast heart rate, nausea, diarrhoea, muscle rigidity and twitching, overactive reflexes with clonus, and tremor. It can be fatal (rasagiline label, US Food and Drug Administration, FDA, section 5.2). According to the European rasagiline summary of product characteristics (SmPC), post-marketing reports describe potentially fatal serotonin syndrome with agitation, confusion, rigidity, fever and myoclonus in patients who took rasagiline with antidepressants, pethidine, tramadol, methadone or propoxyphene (rasagiline SmPC, European Medicines Agency, EMA, section 4.8). Symptoms usually start within several hours to a few days of combined use but may start later. The other form of interaction between monoamine oxidase (MAO) inhibitors and opioids is opioid toxicity with respiratory depression and coma (FDA tramadol label, sections 5.9 and 7). With MAO inhibitors, tramadol also carries a higher risk of seizures (FDA tramadol label, section 5.10).
Management
The combination is contraindicated. The Spanish tramadol summary of product characteristics (SmPC) prohibits tramadol in patients who are taking monoamine oxidase (MAO) inhibitors or have taken them within the last 14 days (tramadol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3). According to its own SmPC, rasagiline is an MAO type B inhibitor (rasagiline SmPC, European Medicines Agency, EMA, section 5.1). The US labels contraindicate rasagiline with tramadol by name and tramadol with all MAO inhibitors (rasagiline and tramadol labels, US Food and Drug Administration, FDA, section 4). The European rasagiline SmPC contraindicates only pethidine among opioids, but its adverse reactions section reports serotonin syndrome with tramadol (rasagiline SmPC, EMA, sections 4.3 and 4.8). Start tramadol no earlier than 14 days after stopping rasagiline (FDA rasagiline label, section 4; tramadol SmPC, AEMPS, section 4.3, and FDA label, section 4). The documents give no interval between the last dose of tramadol and the first rasagiline tablet. If serotonin syndrome is suspected, stop tramadol (FDA tramadol label, section 5.9). Stopping serotonergic drugs usually brings rapid improvement (tramadol SmPC, AEMPS, section 4.4). Warn patients taking rasagiline that pethidine and some other painkillers must not be used with it (FDA rasagiline label, section 17).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- FDA: Tramadol hydrochloride tablets prescribing information (Amneal) (2026)– FDA label, Amneal Pharmaceuticals NY LLC, DailyMed setid 8ec4e4e5-a56e-4198-8428-6b770b9bf27d, revised 06/2026, sections 4, 5.9, 5.10, 7 and 17
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.5 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Tramadol, Adolonta 50 mg cápsulas (nº registro 59088), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59088 (Adolonta 50 mg cápsulas duras, Grünenthal Pharma), revisión 11/2025 (texto revisado 10/2025), secciones 4.3, 4.4, 4.5 y 5.1